Secnidazole for treatment of bacterial vaginosis: a systematic review

Mohamed A. Abd El Aziz, Foruzan Sharifipour, Parvin Abedi*, Shayesteh Jahanfar and Helen Marie Judge

Abstract

Background: Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV.

Methods: The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3.

Results: Our search found six trials involving 1528 participants. Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89–14.60, \( p < 0.00001 \)) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51–14.84, \( p = 0.008 \)). Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.23–25.33, \( p = 0.0009 \)) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06–382.45, \( p = 0.05 \)). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole.

The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole.

Conclusion: This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g. Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.

Keywords: Secnidazole, Metronidazole, Bacterial vaginosis, Systematic review, Ornidazole

Background

Bacterial vaginosis (BV) is a type of vaginitis that results from change in bacterial vaginal flora due to the loss of hydrogen-peroxide generating lactobacilli and excessive growth of anaerobic bacteria and Gardnerella vaginalis. BV is the most common gynecologic infection in women of childbearing age, affecting 40–50% of women within this age worldwide [1]. The vaginal flora contains various lactobacilli species that help maintain vaginal acidity (pH < 4.5) [2]. Vaginal microbiology is determined by factors that affect the strength of bacteria to survive, including vaginal pH, the presence of lactic acid produced by lactobacilli and hormonal agents such as estrogen, which fills the epithelial cells of the vagina with glycogen and is converted to lactic acid by lactobacilli [3]. The incidence of BV in the United States is 29.2%, which affects approximately 21 million women, and this disorder is the leading cause of 10 million annual visits due to the vaginitis [4]. BV’s clinical symptoms are characterized by increased discharge which smells like...
fish and is uniform, dilute and grayish in color [5]. The known risk factors for this type of vaginitis include poor socioeconomic status, poor health level, early sexual activity, multiple sexual partners, psychological stress, and biogenic factors [6]. Based on clinical criteria, the clinical diagnosis of BV is confirmed if there are at least three criteria. These criteria include: 1. Vaginal discharge that is uniform and homogeneous, and is gray or white to yellowish in color, 2. PH of vaginal discharge equal or greater than 4.5, 3. Positive whiff test (amine odor after adding 10% potassium hydroxide to vaginal discharge) and the presence of clue cells in the vaginal mucus smear sample (at least 1 in 5 cells of the vaginal epithelium) [7].

Treatment of bacterial vaginosis
Failure to properly treat bacterial vaginosis can lead to serious complications such as postpartum endometritis, pelvic inflammatory disease, premature rupture of the fetal membranes, preterm delivery, increased risk of post-hysterectomy infection, chorioamnionitis, spontaneous abortion, recurrent urinary tract infection and increased risk of intraepithelial cervical neoplasia [8, 9].

Other complications of this infection include increased risk of sexually transmitted infections such as chlamydia, gonorrhea, HIV, and herpes simplex type 2, [10] so early diagnosis of BV and its treatment are important.

Usual treatments for BV include oral metronidazole 500 mg bid for 7 days, vaginal metronidazole gel 0.75% per day for 5 days, and vaginal clindamycin 2% per day for 7 days [11]. In spite of access to these regimens, there is 30% recurrence 60 to 90 days after treatment, which increases over time (50% in 12 months) [12]. Other treatments include actinazole from the nitroimidazole group [13] with a longer half-life than metronidazole (approximately 17 h compared to 8 h) for the treatment of vaginosis and strains of trichomoniasis are in usage in Asia and Europe [14]. In laboratory studies, the antimicrobial properties of acetyazol have been shown against many bacterial species involved in vaginosis.

Various clinical trials have reported the effects of one or two grams of oral secnidazole on the improvement of BV [15–18]. Despite the numerous clinical trials conducted in this area, there is no review study that compares the therapeutic effects of secnidazole with other treatments regarding the improvement of symptoms of BV. Therefore, the aim of the present systematic review is to examine the evidence from randomized clinical trials on the therapeutic effects of secnidazole on BV and compare it with metronidazole or placebo.

Methods
Types of studies
We recruited Randomized controlled trials (RCTs).

Types of participants
Women (of all ages) diagnosed with bacterial vaginosis using Amsel criteria were recruited for this study.

Types of interventions
Eligible trials compared single or combination treatment regimen (secnidazole) compared with conventional treatment (metronidazole) or placebo for bacterial vaginosis. We had no restriction regarding route of administration, dose, frequency or duration.

Types of outcomes

Primary outcomes
1. Clinical cure rate.
2. Microbiologic cure rate.
3. Therapeutic cure rate.

Secondary outcomes
Adverse events such as yeast infection, valvovaginal pruritus, nausea, or increase liver enzymes.

We followed the Cochrane Collaboration reviewed methods for collection and analysis summary data. There was no limitation regarding to publication status, country, duration of follow-up or language. The search terms are presented in Additional file 1. We conducted the search on Cochrane Library (CENTRAL 2018), MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018).

Two reviewers (FS, HJ) independently examined title/abstracts of all studies according to our inclusion criteria. One of the review authors (MAA) checked for discrepancies which were resolved by discussion. One review author (MAA) entered the data into Review Manager 5.3. A second author independently checked the data (FS). Using a pre-designed data extraction sheet, two reviewers (MAA, FS) independently extracted the data from the included studies. The relevant data extracted from the included studies were study details (dates when the research was conducted, geographic location, participant inclusion criteria, funding sources, publication date), participant characteristics, interventions details (type, duration, route of administration, dose), outcome details (type of outcome, outcome assessment method), and bias assessment details (data necessary to assess the risk of bias, as described below).

Risk of bias assessment
We assessed the following risk of bias domains for each trial: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias as shown in Fig. 1 [19].
Measures of treatment effect

All our outcomes were binary outcomes, so we calculated the odds ratio (OR) with 95% confidence intervals (CI). The unit of analysis was the participant.

Meta-analysis

Meta-analysis was only feasible for particular topics that at least two or more than two studies addressed those topics.

Results

Our search strategies found six trials involving 1528 randomized participants that met our inclusion criteria (PRISMA Chart, Fig. 2) [13, 16, 17, 20–22].

The included trials were conducted between 1996 and 2014. Two out of our six studies have conducted in the USA. The remaining studies were conducted in France, Venezuela, Turkey and India. One trial was phase II, five were phase III (Table 1).

We excluded four studies, because we were not able to find the full texts of those studies or they did not have a control group [23–26].

Risk of bias in included studies

Four out of six trials were rated as having a low risk of selection bias as they used appropriate random sequence generation method. However, only one trial had low risk for allocation concealment bias. One trial stated that the investigators were not blinded to the treatment. The remaining four trials reported no information for allocation concealment, thus they were rated having an unclear risk for selection bias (Fig. 1). For assessment the risk of bias and quality of studies, we used Grading of Recommendations, Assessment, Development and Evaluation (GRADEpro, Table 2).

Effects of interventions

2 g secnidazole versus placebo

The effect of intervention in terms of clinical cure of patients with three or less episodes of BV in the last year is illustrated in Fig. 3. Two studies [17, 20] with total participants of 210 were recruited in the meta-analysis. As evident from this figure, treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year 7.54 (95% CI: 3.89–14.60, \( p < 0.00001 \)) or in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51–14.84, \( p = 0.008 \)) (n = 78). The level of heterogeneity was high (I² = 76%) in the later analysis and did not change using random effect model. Because only two studies were in the meta-analysis, the sensitivity analysis was not applicable (Fig. 3) [17, 20].

The microbiologic cure rate of 2 g secnidazole versus placebo was assessed in one study [17] (n = 124). Results showed that 2 g secnidazole could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.36, 95% CI: 3.10–28.11, \( p = 0.001 \)) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06–382.45, \( p = 0.05 \)). Also the Hiller’s study (n = 124) showed that therapeutic cure rate of 2 g secnidazole versus placebo was 9.34 (OR: 9.34, 95% CI: 3.10–28.11, \( p = 0.0001 \)) [17].

2 g versus 1 g secnidazole

The comparison of effect of 2 g versus 1 g secnidazole is illustrated in Fig. 4 (n = 202). As shown in this figure the clinical cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole (OR: 2.06, 95% CI: 1.02–4.16, \( p = 0.04 \)) [16, 17].

Two studies comprising 202 women used 2 g versus 1 g secnidazole for assessing the microbiological effect [16, 17].
There was a significant difference between 2 g versus 1 g secnidazole regarding microbiological effect (OR: 2.21, 95% CI: 1.07–4.60, $P = 0.03$). The therapeutic cure rate in patients who received 2 g secnidazole was significantly more than that in 1 g secnidazole (OR: 8.07, 95% CI: 2.81–123.17, $p = 0.0001$) ($n = 125$) [17].

**1 g secnidazole versus placebo**

The clinical cure rate of 1 g secnidazole versus placebo was evaluated in 126 women and results showed that secnidazole was significantly more effective than placebo (OR: 5.45, 95% CI: 2.33–12.75, $p = 0.0001$) (Fig. 5) [17].
| Reference          | Methods          | Participants                                      | Interventions                      | Outcomes                          | Notes                                      |
|--------------------|------------------|---------------------------------------------------|------------------------------------|------------------------------------|--------------------------------------------|
| Hillier, 2017 [17] | - Parallel design | - Enrolled: 215                                  | 1. Secnidazole 2 g single oral dose | - Primary:                         | - Trial registration number: ClinicalTrials.gov, NCT02147899 |
|                    | - three arms     | - Randomized: Secnidazole 1 g: 71 patients,      | 2. Secnidazole 1 g single oral     | Clinical cure: based on the 1998   | - A priori sample size estimation: yes     |
|                    | - Phase II       | Secnidazole 2 g: 72 patients, and placebo: 72    | dose                                | FDA guidance regarding evaluation  | - Trial conduction date: between May 28    |
|                    |                  | patient                                         | 3. Placebo                         | of treatment for bacterial          | and September 5, 2014                      |
|                    |                  | - Age: Median (min,max): Secnidazole 2 g: 31     |                                    | vaginosis: 1) Normal                | - Funding for this study was provided to   |
|                    |                  | (19, 54); Secnidazole 1 g: 34 (19, 49);         |                                    | vaginal discharge, 2) negative      | Magee-Womens Research Institute (Hillier), |
|                    |                  | Placebo: 33 (19, 49)                             |                                    | 10% potassium hydroxide whiff test,| Drexel University (Nyirjesy), Downtown    |
|                    |                  | - Number of BV episodes in past 12 months        |                                    | and 3) clue cells less than 20%    | Women’s Health Care (Waldbaurn), the       |
|                    |                  | (median(min, max): Secnidazole 2 g: 2 (1, 12);  |                                    | of total epithelial cells on        | University of Alabama (Schwebke), and      |
|                    |                  | Secnidazole 1 g: 1 (1, 13), Placebo: 3 (1, 12); |                                    | microscopic examination of the      | Tidewater Clinical Research, Inc. (Morgan), |
|                    |                  | - Number of BV episodes in past 12 months, n (%): |                                    | vaginal wet mount using saline at   | by Symbionix Therapeutics, LLC, Baltimore, |
|                    |                  | 1) ≤ 3: Secnidazole 2 g: 41 (66.1); Secnidazole 1 |                                    | the test of cure visit.             | MD                                        |
|                    |                  | g: 44 (68.8); Placebo: 43 (69.4).                |                                    | - Secondary:                       | - Sponsor: Not reported                    |
| Nunez, 2005 [16]   | - Parallel design | - Enrolled: 76                                   | 1. single oral dose of Secnidazole 1 | 1) Nugent score                     | - Trial registration number: Not reported   |
|                    | - Two arm        | - Randomization: 1 g single oral dose Secnidazole | g and 2) Therapeutic cure:        | (microbiologic cure): with a score  | - Trial conduction date: between March 2007|
|                    | - Phase III      | 44 patients, 2 g single oral dose Secnidazole: 32| defined as meeting the criteria     | of 0–3 considered Lactobacillus-     | and July 2008                              |
|                    | - Country: Manuel Noriega Trigo Hospital, Maracaibo, Venezuela | patients | for both clinical and microbiologic | dominant and a score of 4 or greater | - Funding for this study was provided to   |
|                    |                  | - Age: Mean (SD): Secnidazole 2 g: 39.4 (9.9);  | cure criteria: Both clinical and   | considered abnormal.                | Magee-Womens Research Institute (Hillier), |
|                    |                  | Secnidazole 1 g: 41.1 (11.6)                     | microbiologic cure criteria.       | - Safety: were based on the         | Drexel University (Nyirjesy), Downtown     |
|                    |                  | - Number of BV episodes in past 12 months: Not   | defined as the incidence, intensity, and type of adverse events and changes in patients’ physical examination findings, vital signs, and clinical laboratory results, | incidence, intensity, and type of adverse events and changes in patients’ physical examination findings, vital signs, and clinical laboratory results, |
|                    |                  | reported                                          |                                    | - Safety: were based on the         | - Sponsor: Not reported                    |
|                    |                  | - Baseline nugent score: median (min, max):      |                                    | incidence, intensity, and type of adverse events and changes in patients’ physical examination findings, vital signs, and clinical laboratory results, | - Sponsor: Not reported                    |
|                    |                  | Secnidazole 2 g: 8 (4, 10); Secnidazole 1 g: 9 (5, 10); Placebo: 8 (4, 10) |                                    | - Safety: were based on the         | - Sponsor: Not reported                    |
| Bohbot, 2010 [13]  | - Parallel design | - Number enrolled: 577                            | 1. Intervention: 500 mg metronidazole twice per day for 7 days | - Secondary: | - Trial registration number: Not reported   |
|                    | - Two arm        | - Randomized: 1) metronidazole group: 237 in modified intention to treat analysis group and 2) Secnidazole group: 243 in modified intention to treat analysis group | 2. Control: single oral dose of Secnidazole 2 g | Cytoclogic cure: was defined as an absence of G. vaginalis on a Pap smear | - Trial conduction date: between March 2007 and July 2008 |
|                    | - Phase III      | - Age: mean age: 36 years in both groups.         |                                    |                                    | - Funding for this study was provided to   |
|                    | - Country: France: Multicenter (27 centers) | - Number of BV episodes in past 12 months:       |                                    |                                    | Magee-Womens Research Institute (Hillier), |
|                    |                  | Approximately 28% of patients (secnidazole: 27.2%; metronidazole: 28.6%) had experienced at least one episode of BV during the two years preceding |                                    |                                    | Drexel University (Nyirjesy), Downtown     |
|                    |                  | - Trial registration number: ClinicalTrials.gov, NCT02147899 |                                    |                                    | Women’s Health Care (Waldbaurn), the       |
|                    |                  | - A priori sample size estimation: No             |                                    |                                    | University of Alabama (Schwebke), and      |
|                    |                  | - Trial conduction date: Not reported             |                                    |                                    | Tidewater Clinical Research, Inc. (Morgan), |
|                    |                  | - Funding for this study was provided to Magee-  |                                    |                                    | by Symbionix Therapeutics, LLC, Baltimore, |
|                    |                  | Womens Research Institute (Hillier), Drexel       |                                    |                                    | MD                                        |
|                    |                  | University (Nyirjesy), Downtown Women’s Health    |                                    |                                    | - Sponsor: Not reported                    |
| Reference          | Methods          | Participants                                      | Interventions                                                                 | Outcomes                                                                                           | Notes                                                                                          |
|--------------------|------------------|--------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Saracoglu, 1998 [22] | Parallel design  | 8 arms                                           | Setting the patient in the treatment groups ranged between 19 and 45 with no statistical difference in between. | Clinical cure: Absence of symptoms, vaginal discharge resulting from bacterial vaginosis and clue cells was accepted as cure. | - Trial registration number: Not reported  
- A priori sample size estimation: no  
- Trial conduction date: between January and May 1996  
- Sponsor: Not reported  
- Role of sponsor: No reported |
|                    | - Parallel design| - Phase III                                      | - Country: Turkey: Ankara Numune Hospital Obstetrics and Gynecology Outpatient Clinic  
- Follow-up period: Assessed during first week and after 30-40 days "We called the patients to inform us about their symptoms after the first week and all the patients visited the clinic within 30-40 days for evaluation of the clinical and laboratory results"  
- Unit of randomization: participant  
- Analysis unit: participant | - Number of BV episodes in past 12 months: Not reported  
- Baseline Nugent score: Not reported | 1. oral single dose 2 g Secnidazole  
2. "oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days"  
3. "oral secnidazole 2 g in a single dose and vaginal metronidazole 2X500 mg for 7 days"  
4. oral ornidazole 2X500 mg/day for 5 days and vaginal metronidazole 2X500 mg/day for 7 days;  
5. "vaginal metronidazole 2X500 mg/day for 7 days"  
6. oral ornidazole 2X500 mg/day for 5 days;  
7. vaginal ornidazole 500 mg/day for 5 days  
8. Oral + vaginal ornidazole for 5 days |
| Schwebke, 2017 [20] | Parallel design  | Two arms                                          | Country: USA: Multicenter (21 center in USA).  
- Follow-up period: 21 to 30 days  
- Unit of randomization: participant  
- Analysis unit: participant | - Number of BV episodes in past 12 months: Mean (SD): 1) Secnidazole group: 32 (8.7) and 2) placebo group: 30 (7.6)  
- Number of BV episodes in past 12 months, n (%): 1 ≤5: Secnidazole 2 g: 83 (77.6), Placebo: 43 (75.4); 2  
24: Secnidazole 2 g: 24 (22.4), Placebo: 14 (24.6)  
- Baseline Nugent score: mean (SD): 1) Secnidazole group: 8 (1.8), Placebo group: 9 (1.3) | 1. oral single dose 2 g Secnidazole  
2. placebo | - Primary: "Proportion of clinical outcome responders (CORs): Normal discharge, negative KOH whiff test, and clue cells < 20% at TOC/EOS visit (study days 21–30)"  
- Secondary: "An alternate definition of responder defined as: Normal discharge after treatment or abnormal discharge that is inconsistent with BV, negative KOH whiff test; clue cells < 20% assessed at the interim visit (study days 7–14) and TOC/EOS (study days 21–30)"  
- Safety: "Rates of adverse events (AES), serious AES, vital signs, physical examination findings, and
The microbiologic cure and the therapeutic cure rate of 1 g secnidazole was significantly more than that in the placebo group (OR: 4.25, 95%CI: 1.37–13.18, p = 0.01) and (OR: 3.14, 95% CI: 1.17–8.42, p = 0.02) respectively [17].

**Secnidazole versus metronidazole**

One study [13] recruited 480 women to compare the effect of 2 g secnidazole versus metronidazole (500 mg bid for 5 days). Results showed that there was no significant difference between two groups in terms of clinical cure (OR: 0.87, 95% CI: 0.56–1.34, P = 0.53). Also the effect of 2 g oral secnidazole versus 2 g secnidazole plus vaginal metronidazole was compared in one study with 40 participants and the results showed that there was no significant difference between two groups (OR: 0.11, 95% CI: 0.01–2.08, p = 0.14) [22].

One study recruiting 39 women evaluated the effect of 2 g secnidazole versus 2 g secnidazole plus vaginal ornidazole and results showed no significant difference between two groups (OR: 0.29, 95% CI: 0.03–2.69, p = 0.28) [22]. Also the effect of 2 g oral secnidazole versus 2 g secnidazole plus vaginal metronidazole was compared in one study with 40 participants and the results showed that there was no significant difference between two groups (OR: 0.11, 95% CI: 0.01–2.08, p = 0.14).

**Adverse effect**

The adverse effects that reported in studies that 2 g secnidazole was used versus placebo were yeast infection, vulvovaginal pruritus, dyspareunia, nausea, increase the level of hepatic enzymes such as ALT and AST and headache. There was no significant difference between the two groups in any of the studies regarding adverse effects in 2 g secnidazole versus placebo (n = 233) (OR: 2.24, 95% CI: 0.85–5.94, P = 0.10) or versus 1 g secnidazole (n = 219) (OR: 1.25, 95% CI: 0.65–2.41, P = 0.50) [17, 20].

**Discussion**

This systematic review designed to evaluate the effect of secnidazole on bacterial vaginosis in childbearing women. BV is one of the most prevalent vaginitis in the United States and almost 30% of childbearing aged women are affected with this infection [27]. BV has some consequences such as; endometritis, postpartum fever, cellulitis in the hysterectomy cuff and infection after abortion [28] and also is a risk factor for acquisition of HIV and herpes simplex virus type 2 and other sexually transmitted diseases [29].

The main medication for treatment of BV is metronidazole that has 90% effectiveness, but the recurrence rate is high [30]. Secnidazole is a next-generation of 5-nitroimidazole that has already approved in Europe and Asia as a single dose of 2 g for BV. This medication also was approved to use in the USA in 2004 [31]. The long half-life of secnidazole (17–28.8 h) makes it possible for a single dose to be effective [32]. The food and drug administration (FDA) of the United States recently approved the single 2 g dose of secnidazole for the treatment of BV according to two randomized controlled trials that conducted in the United States [33].
**Table 2** Summary of findings table for presenting risks and quality of evidence about recruited studies

One gr Secnidazole compared to placebo for bacterial vaginosis

Bibliography: secnidazole for bacterial vaginosis. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

| Certainty assessment | No of participants (studies) | Follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | Study event rates (%) | Relative effect (95% CI) | Risk with placebo | Risk difference with 1 g Secnidazole |
|----------------------|-------------------------------|-----------|--------------|---------------|--------------|-------------|-----------------|---------------------------|----------------------|----------------------|-----------------|-----------------------------|
| clinical cure rate   | 126 (1 RCT)                   |           | not serious  | not serious   | not serious  | none        | ★★★★★ HIGH    | 11/62 (17.7%)              | 33/64 (51.6%)        | RR 2.92* (1.64 to 5.19) | 177 per 1000      | 341 more per 1000 (from 114 more to 743 more) |
| clinical cure rate - Clinical cure of pts. with 3 or less episodes of BV in the last year | 87 (1 RCT)                 |           | not serious  | not serious   | not serious  | none        | ★★★★★ HIGH    | 10/43 (23.3%)              | 26/44 (59.1%)        | RR 2.54* (1.40 to 461) | 233 per 1000      | 358 more per 1000 (from 93 more to 840 more) |
| clinical cure rate - Clinical cure of pts. with 4 or more episodes of BV in the last year | 39 (1 RCT)                 |           | not serious  | not serious   | not serious  | very serious* | ★★★★ LOW      | 1/19 (5.3%)               | 7/20 (35.0%)         | RR 6.65 (0.90 to 4909) | 53 per 1000       | 297 more per 1000 (from 5 fewer to 1000 more) |
| Microbiologic cure rate | 126 (1 RCT)                 |           | not serious  | not serious   | not serious  | none        | ★★★★★ HIGH    | 4/62 (6.9%)               | 15/64 (23.4%)        | RR 3.35* (1.26 to 895) | 65 per 1000       | 152 more per 1000 (from 17 more to 513 more) |
| Microbiologic cure rate - Microbiologic cure of pts. with 3 or less episodes of BV in the last year | 87 (1 RCT)                |           | not serious  | not serious   | not serious  | none        | ★★★★★ HIGH    | 4/43 (9.3%)               | 13/44 (29.5%)        | RR 3.18* (1.12 to 898) | 93 per 1000       | 203 more per 1000 (from 11 more to 742 more) |
| Therapeutic cure rate | 126 (1 RCT)                 |           | not serious  | not serious   | not serious  | none        | ★★★★★ HIGH    | 4/62 (6.9%)               | 14/64 (21.9%)        | RR 3.14* (1.17 to 842) | 65 per 1000       | 138 more per 1000 (from 11 more to 479 more) |
**Table 2** Summary of findings table for presenting risks and quality of evidence about recruited studies (Continued)

One gr Secnidazole compared to placebo for bacterial vaginosis

Bibliography: secnidazole for bacterial vaginosis. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

| Study event rates (%) | Relative effect (95% CI) | Anticipated absolute effects |
|-----------------------|--------------------------|-----------------------------|
| With placebo          | With 1 g Secnidazole     | Risk with placebo           | Risk difference with 1 g Secnidazole |
| 4/43 (9.3%)           | 13/44 (29.5%)            | RR 3.18* (1.12 to 8.98)    | 93 per 1000                          | 203 more per 1000 (from 11 more to 742 more) |

Therapeutic cure rate - Therapeutic cure of pts. with 3 or less episodes of BV in the last year

| Study event rates (%) | Relative effect (95% CI) | Anticipated absolute effects |
|-----------------------|--------------------------|-----------------------------|
| With placebo          | With 1 g Secnidazole     | Risk with placebo           | Risk difference with 1 g Secnidazole |
| 87 (1 RCT)            | not serious              | RR 3.18* (1.12 to 8.98)    | 93 per 1000                          | 203 more per 1000 (from 11 more to 742 more) |

Therapeutic cure rate - Therapeutic cure of pts. with 4 or more episodes of BV in the last year

| Study event rates (%) | Relative effect (95% CI) | Anticipated absolute effects |
|-----------------------|--------------------------|-----------------------------|
| With placebo          | With 1 g Secnidazole     | Risk with placebo           | Risk difference with 1 g Secnidazole |
| 87 (1 RCT)            | not serious              | RR 3.18* (1.12 to 8.98)    | 93 per 1000                          | 203 more per 1000 (from 11 more to 742 more) |

* significant (p < 0.05)

CI: Confidence interval, RR: Risk ratio

Explanations:

- A very wide confidence interval
- Large confidence interval

Bold data are significant
The results of this systematic review showed that 1 g secnidazole could significantly improve the clinical cure rate in women with BV compared to placebo, but the microbiological cure rate was not significantly different from placebo in women with 4 or more episodes of BV in the last year.

Our results also revealed that 2 g secnidazole significantly could treat BV in women with three or less or four and more episodes of BV in the last year in compare to placebo. Further, our results showed that 2 g secnidazole was significantly more effective in terms of clinical cure rate and microbiological impact than that of 1 g secnidazole.

We found only one study that compared the effect of 2 g secnidazole with metronidazole (500 mg bid for 5 days) or 2 g single dose of metronidazole. The results revealed no significant difference regarding clinical cure rate in both methods.

The diagnosis of BV is according to the Amsel criteria (at least three criteria should be present) including; homogenous grayish-white vaginal discharge, vaginal pH > 4.5, positive whiff test (fish odor with adding a drop of 10% potassium hydroxide to the vaginal discharge) and presence of more than 20% clue cells in the wet smear of vaginal discharge [34]. The clinical cure of BV are including; a negative test for amino odor after adding 10% potassium hydroxide solution to vaginal discharge, the number of clue cells less than 20% and pH of vaginal discharge < 4.5 [35]. In all studies recruited in this systematic review the Amsel criteria was used for clinical cure rate of BV.

Strengths and limitations of the study
This is the first time that we evaluated the effect of secnidazole on BV in a systematic review study. In this systematic review we only found six studies and the meta-analysis was only possible in some cases. High level of heterogeneity was observed in some studies that meta-analyses were performed. Because in most cases there were only two studies in the meta-analysis, the sensitivity analysis was not possible. Therefore the results should be considered with caution.
Conclusion
This systematic review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g. Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole. Secnidazole can be considered as an alternative to the treatment of BV for women who have experienced adverse effects or had a recurrence with current medications of BV.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12905-019-0822-2.

Abbreviations
Bid: twice (two times) a day; BV: Bacterial vaginosis; RevMan: Review Manager

Acknowledgements
N/A

Authors’ contributions
Conceptualization: MAA, HMJ and FS. Search and screening: MAA, HMJ and FS. Analyses and interpretation: MAA, PA and SJ. Writing and finalizing the manuscript: FS, PA and SJ. All authors read and approved the final version of the study.

Funding
No funding was received for this research.

Availability of data and materials
Data sharing is not applicable for this study. There is no datasets were used for this study.

Ethics approval and consent to participate
N/A

Consent for publication
N/A

Competing interests
Parvin Abedi and Shayesteh Jahanfar are both associate editors of BMC Pregnancy and Childbirth and other than this, the authors declare that they have no competing interests.

Author details
1Department of obstetrics and gynecology, Benha University Hospital, Benha University, Benha, Egypt. 2Midwifery Department, Kermanshah University of Medical Sciences, Kermanshah, Iran. 3Midwifery Department, Menopause Andropause Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4School of Health Sciences, Health Professions 2239, Central Michigan University, Michigan, USA. 5School of Medicine, Atlantic University, Saint Lucia, West Indies, USA.

Received: 10 April 2019 Accepted: 26 September 2019
Published online: 21 October 2019

References
1. Gibbs RS, Karlah BY, Haney AF, Nygaard IE. Danforth’s Obstetrics and Gynecology. 10th ed. 2008 Lippincott Williams and Wilkins. Philadelphia. PA19106 USAP.625–640.
2. Biggs WS, Williams RM. Common gynecologic infections. Prim Care 2009; 36(1):33–51, viii. doi: https://doi.org/10.1016/j.pop.2008.10.002.
3. Terraf M, Tomás J. Nader - Macías M, Silva C. screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components. J Appl Microbiol. 2012;113(6):1517–29.
4. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States association with symptoms sexual behaviors and reproductive health. Sex Transm Dis. 2007; 34(11):864–9.
5. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women,” Cochrane Database Syst Rev. 2009 Jul 8(3):CD006055. doi: https://doi.org/10.1002/14651858. CD006055.pub2.
6. Li XD, Tong F, Zhang XJ, Pan WJ, Chen ML, Wang CC, Li X, et al. Incidence and risk factors of bacterial vaginosis among pregnant women: a prospective study in Maanshan city, Anhui Province, China. J Obstet Gynaecol Res. 2015 Aug41(8):1214–22. https://doi.org/10.1111/jog.12704.
7. Armstrong NR, Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health 2009 Aug;1(9):59–65.
8. Bacterial vaginosis - CDC fact sheet. (2017, February 16). Retrieved from https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm. Accessed 16 Feb 2017.
9. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis. 2009;199(5):680–3.
10. Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis – limitations and need for innovation. J Infect Dis. 2016;214(Supp 1):S14–20.
11. CDC. Sexually transmitted disease treatment guidelines. MMWR. 2015;64:1–137.
12. Sobel JD. Bacterial Vaginosis. Waltham, MA: Uptodate 2013. Available at: www.uptodate.com/contents/bacterialvaginosis?topicKey=OBGYNiL2FS451
   &elap Accessed 6 April 2017.
13. Bohbot JM, Vicart E, Fagnon D, Braun M. Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole. Infect Dis Obstet Gynecol. Volume 2010, Article ID 705692, 6 pages. https://doi.org/10.1155/2010/705692
14. Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978;54:77–80.
15. Donners G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65:462–73.
16. Núñez JT, Gómez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet. 2005;88:281–5.
17. Hillier S, Nyirjesy P, Waldbaum A, Schwabek J, Morgan F, Adetoro N, Braun C. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017;130(2):379.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ online 2009;339 b2700.
19. Higgins, J.D., Altman, D.G., Tetzlaff, J., et al. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. J. Wiley, 2011.
20. Schwabek J, Morgan FG Jr, Kolunt W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1–9. https://doi.org/10.1016/j.ajog.2017.08.017.
21. Thulkar J, Kripiani A, Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012 Mar-Apr;44(2):243–5. https://doi.org/10.4103/0253-7613.93859.
22. Saracoğlu F, Göll K, Sahin I, Türkkan B, Atalay C, Öztöpçu C. Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole. Int J Gynaecol Obstet. 1998;62(1):59–61.
23. Wang FM, Qian XD, Xu H, Yu HY. Efficacy of 5-nitroimidazole derivatives in treatment of bacterial vaginosis. Zhonghua Yi Xue Za Zhi. 2008 Aug 12;88(31):2201–3.
24. Tariq N, Basharat A, Khan DH, Fahim A, Khan MH. Treatment for Symptomatic Bacterial Vaginosis: A Randomized Controlled Trial. J Coll Physicians Surg Pak. 2017;27(11):2743–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776667/
25. Tohoto E, Chihihongwongwathana S, Dalay S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol. 2006;195:1198.
26. Tohoto E, Chihihongwongwathana S, Dalay S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol. 2006;195:1198.
27. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761.
28. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in south African women: a nested case-control study. J Infect Dis. 2005;192:1372.
29. Amaya-Guio J, Viveros-Carreno DA, Sierra-Barrios EM, Martínez-Velasquez MY, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701.
30. Nyirjesy P, Schwabek JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018;13(5). https://doi.org/10.2217/fmb-2017-0270.
31. Nagel JL, Aronoff DM, Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 8th Edi; 2015.
32. SOLOSEC (secnidazole) oral granules Initial U.S. Approval: 2017: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf. 2017.
33. Eschenbach DA, Hillier S, Crichtlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158:813.
34. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.